Therefore, the discovery of new selective TRPM8 antagonists hold promising results in PC therapy, since the lead compounds we used combine the selective modulation of AR-mediated rapid actions with the release of intracellular calcium. The gene discussed is TRPM8; the disease is pachyonychia congenita.